Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/33260
Title: ACE activity is modulated by the enzyme alpha-galactosidase A
Authors: Batista, Elice Carneiro
Carvalho, Luiz Roberto
Casarini, Dulce Elena [UNIFESP]
Carmona, Adriana Karaoglanovic
Santos, Edson Lucas dos
Silva, Elton Dias da
Santos, Robson Augusto dos
Nakaie, Clovis Ryuichi
Munoz Rojas, Maria Veronica
Oliveira, Suzana Macedo de
Bader, Michael
D'Almeida, Vania [UNIFESP]
Martins, Ana Maria [UNIFESP]
Souza, Kely de Picoly
Pesquero, Joao Bosco [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Max Delbruck Ctr Mol Med MDC
Genzyme Brasil
Universidade Federal de Minas Gerais (UFMG)
Fed Univ Grande Dourados
Hosp Sao Vicente de Paulo
Keywords: ACE
Angiotensin
Biochemistry
Biology
Blood pressure
Angiotensin I-converting enzyme alpha-galactosidase A
Fabry disease
ACE inhibitors
Issue Date: 1-Jan-2011
Publisher: Springer
Citation: Journal of Molecular Medicine-jmm. New York: Springer, v. 89, n. 1, p. 65-74, 2011.
Abstract: Fabry disease is a multisystem X-linked disorder resulting from alpha-galactosidase A (alpha-GalA) gene mutations leading to the accumulation of globotriaosylceramide mainly in endothelium compromising heart, kidney, and brain. in Fabry patients, progressive renal failure is frequently treated with angiotensin I-converting enzyme (ACE) inhibitors. We were interested in the possible interactions between ACE inhibitors therapy and the only causative therapy for Fabry disease, the enzyme replacement therapy (ERT) using recombinant human alpha-GalA (rh alpha-GalA). Our results suggest that ACE activity was significantly inhibited in plasma of Fabry patients and the blood pressure level decreased just after ERT (at the end of the rh alpha-GalA infusion). Interestingly, 2 weeks later, ACE activity was significantly upregulated and the plasma levels of angiotensin II increased in the patients treated with rh alpha-GalA following the elevations of ACE activity. the same inhibitory effect on ACE activity was also observed in rats after rh alpha-GalA infusion. Furthermore, ACE activity in CHO cells transfected with the human ACE was inhibited dose and time-dependently by rh alpha-GalA. in vitro, the incubation of plasma from healthy volunteers with rh alpha-GalA significantly reduced ACE activity. Finally, rh alpha-GalA also inhibited ACE activity and released galactose residues from purified rabbit lung ACE dose-dependently. in summary, our results suggest that rh alpha-GalA interacts with ACE and inhibits its activity, possibly by removing the galactose residues from the enzyme. This modulation might have profound impact on the clinical outcome of Fabry patients treated with rh alpha-GalA.
URI: http://repositorio.unifesp.br/handle/11600/33260
ISSN: 0946-2716
Other Identifiers: http://dx.doi.org/10.1007/s00109-010-0686-2
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.